Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes

被引:144
作者
Avolio, C
Ruggieri, M
Giuliani, F
Liuzzi, GM
Leante, R
Riccio, P
Livrea, P
Trojano, M
机构
[1] Univ Bari, Policlin, Dept Neurol & Psychiat Sci, I-70124 Bari, Italy
[2] Univ Foggia, Neurol Unit, Foggia, Italy
[3] Univ Bari, Dept Biochem & Mol Biol, Bari, Italy
[4] Univ Basilicata, DBAF, Dept Biol, I-85100 Potenza, Italy
关键词
matrix metalloproteinases; tissue inhibitors of metalloproteinases; multiple sclerosis;
D O I
10.1016/S0165-5728(03)00006-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In multiple sclerosis (MS), matrix metalloproteinase (MMP) activity in tissues is the result of a balance between MMPs and their tissue inhibitors (TIMPs). MMP-9 predominates in acute MS lesions and is inhibited by TIMP-1, while MMP-2 may participate in the remodeling of the extracellular matrix (ECM) such as in chronic disease and is inhibited by TIMP-2. These differences may be reflected in serum and cerebrospinal fluid (CSF). We have tried to characterize MMP-2 and MMP-9 activities, in relation to their respective TIMPs, 2 and 1, as a factor of different types of the disease, as this information was not previously clearly stated. We found the MMP-2/TIMP-2 ratio in serum to show higher values in secondary progressive (SP, p = 0.02) and primary progressive (PP, p = 0.01) MS than short disease duration (SDD) relapsing-remitting (RR) MS, but not different from the healthy control (HC) group. Whereas the MMP-9/TIMP-1 ratio in serum showed higher (p = 0.04) values in SDD RR MS than PP but also in active patients, evaluated either clinically (p = 0.006) or from the magnetic resonance imaging (MRI, p < 0.05), compared to inactive disease. CSF MMP to TIMP ratios did not differ between MS subtypes, suggesting systemic rather CNS-restricted changes. These results show that an increase in MMP-2/TIMP-2 ratio marks chronic progression in MS, but it is as high as in HC, and also confirm that high MMP-9 activity characterizes short duration relapsing and active forms of the disease. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 55 条
[1]   CEREBROSPINAL-FLUID IN THE DIAGNOSIS OF MULTIPLE-SCLEROSIS - A CONSENSUS REPORT [J].
ANDERSSON, M ;
ALVAREZCERMENO, J ;
BERNARDI, G ;
COGATO, I ;
FREDMAN, P ;
FREDERIKSEN, J ;
FREDRIKSON, S ;
GALLO, P ;
GRIMALDI, LM ;
GRONNING, M ;
KEIR, G ;
LAMERS, K ;
LINK, H ;
MAGALHAES, A ;
MASSARO, AR ;
OHMAN, S ;
REIBER, H ;
RONNBACK, L ;
SCHLUEP, M ;
SCHULLER, E ;
SINDIC, CJM ;
THOMPSON, EJ ;
TROJANO, M ;
WURSTER, U .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (08) :897-902
[2]   Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke [J].
Anthony, DC ;
Ferguson, B ;
Matyzak, MK ;
Miller, KM ;
Esiri, MM ;
Perry, VH .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1997, 23 (05) :406-415
[3]   Matrix metalloproteinases in multiple sclerosis - Targets of therapy or markers of injury? [J].
Bever, CT ;
Rosenberg, GA .
NEUROLOGY, 1999, 53 (07) :1380-1381
[4]   Tissue inhibitors of metalloproteinases: evolution, structure and function [J].
Brew, K ;
Dinakarpandian, D ;
Nagase, H .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283
[5]   Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview [J].
Chandler, S ;
Miller, KM ;
Clements, JM ;
Lury, J ;
Corkill, D ;
Anthony, DCC ;
Adams, SE ;
Gearing, AJH .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (02) :155-161
[6]   The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution [J].
Cuzner, ML ;
Gveric, D ;
Strand, C ;
Loughlin, AJ ;
Paemen, L ;
Opdenakker, G ;
Newcombe, J .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (12) :1194-1204
[7]  
Dubois B, 1998, MULT SCLER J, V4, P74
[8]   Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis [J].
Filippi, M ;
Wolinsky, JS ;
Sormani, MP ;
Comi, G .
NEUROLOGY, 2001, 56 (03) :422-423
[9]   Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients [J].
Galboiz, Y ;
Shapiro, S ;
Lahat, N ;
Rawashdeh, H ;
Miller, A .
ANNALS OF NEUROLOGY, 2001, 50 (04) :443-451
[10]   GELATINASE IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS AND OTHER INFLAMMATORY NEUROLOGICAL DISORDERS [J].
GIJBELS, K ;
MASURE, S ;
CARTON, H ;
OPDENAKKER, G .
JOURNAL OF NEUROIMMUNOLOGY, 1992, 41 (01) :29-34